S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

CRISPR Therapeutics Stock Forecast, Price & News

-2.13 (-2.63%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.18 million shs
Average Volume
1.61 million shs
Market Capitalization
$6.03 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRISPR Therapeutics logo

About CRISPR Therapeutics

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.


CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 1-Year Low at $77.42
November 24, 2021 |  americanbankingnews.com
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week Low at $82.76
November 18, 2021 |  americanbankingnews.com
CRISPR Therapeutics (NASDAQ:CRSP) Sets New 12-Month Low at $89.31
November 10, 2021 |  americanbankingnews.com
CRISPR Therapeutics (NASDAQ:CRSP) Issues Quarterly Earnings Results
November 6, 2021 |  americanbankingnews.com
Why CRISPR Therapeutics Stock Fell 18.4% in October
November 4, 2021 |  finance.yahoo.com
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $172.00
November 4, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$720 thousand
Book Value
$32.84 per share


Net Income
$-348.86 million
Pretax Margin




Free Float
Market Cap
$6.03 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.27 out of 5 stars

Medical Sector

299th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

48th out of 201 stocks

Analyst Opinion: 4.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics
or view top-rated stocks.

How has CRISPR Therapeutics' stock been impacted by Coronavirus (COVID-19)?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRSP stock has increased by 82.0% and is now trading at $78.79.
View which stocks have been most impacted by COVID-19

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 5,580,000 shares, an increase of 15.8% from the October 14th total of 4,820,000 shares. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is presently 4.4 days. Approximately 8.0% of the shares of the stock are sold short.
View CRISPR Therapeutics' Short Interest

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for CRISPR Therapeutics

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Wednesday, November, 3rd. The company reported ($1.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.75) by $0.08. CRISPR Therapeutics had a net margin of 45.64% and a trailing twelve-month return on equity of 19.19%.
View CRISPR Therapeutics' earnings history

What price target have analysts set for CRSP?

16 brokerages have issued 1-year target prices for CRISPR Therapeutics' shares. Their forecasts range from $101.00 to $210.00. On average, they anticipate CRISPR Therapeutics' share price to reach $160.40 in the next year. This suggests a possible upside of 103.6% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics
or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about CRISPR Therapeutics stock?

Here are some recent quotes from research analysts about CRISPR Therapeutics stock:
  • 1. SVB Leerink LLC analysts commented, " (10/19/2021)
  • 2. According to Zacks Investment Research, "CRISPR Therapeutics' lead pipeline candidate CTX001, a CRISPR gene-edited therapy, is being developed for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in collaboration with Vertex. If successfully developed, CTX001 can reap huge profits as both diseases have a high unmet medical need. The company’s other pipeline candidates are in early-stage development for various cancer indications. However, in absence of a marketed product, it is solely dependent on Vertex for collaborations revenues, which remains a constant woe. Moreover, its candidates are years away from achieving commercialization. Acute competition is also a worry for CRISPR Therapeutics as some companies are developing gene-edited therapies. Shares of the company have outperformed the industry year to date." (2/1/2021)

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:
  • Rodger Novak, Chairman & President
  • Samarth Kulkarni, Chief Executive Officer & Director (LinkedIn Profile)
  • Lawrence O. Klein, Chief Operating Officer
  • Brendan Smith, Senior VP, Chief Financial & Accounting Officer
  • Tony W. Ho, Executive VP, Head-Research & Development

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (4.30%), BlackRock Inc. (1.48%), Macquarie Group Ltd. (1.29%), Bellevue Group AG (1.27%), Morgan Stanley (0.76%) and Versant Venture Management LLC (0.65%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics

Which major investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Two Sigma Investments LP, Clough Capital Partners L P, Macquarie Group Ltd., Jane Street Group LLC, First Republic Investment Management Inc., Nikko Asset Management Americas Inc., and Citadel Advisors LLC. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics
or view top insider-selling stocks.

Which major investors are buying CRISPR Therapeutics stock?

CRSP stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Goldman Sachs Group Inc., SG Americas Securities LLC, Nordea Investment Management AB, Jennison Associates LLC, BlackRock Inc., Wilbanks Smith & Thomas Asset Management LLC, and Morgan Stanley.
View insider buying and selling activity for CRISPR Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $78.79.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $6.03 billion and generates $720 thousand in revenue each year. The company earns $-348.86 million in net income (profit) each year or $4.76 on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 410 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

Where are CRISPR Therapeutics' headquarters?

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at s[email protected].

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.